SMH
·general
·3 hours ago
Proteomics diagnostic tests shift from lab coats to commercial launch
Proteomics International Laboratories transitioned from research to commercial operations on October 24, unveiling a three-year plan to monetize its diagnostics tests. The portfolio includes PromarkerD, which predicts diabetes-related kidney issues, and other tests targeting oesophageal cancer and endometriosis. The company aims for significant market penetration by FY28, focusing on distributor partnerships and reimbursement submissions.
Summary by Glance · SMH
Next
Loving doing this? 🎉
Take it further — get the full app and never miss a moment of what's happening in Australia.
Breaking news alerts
Instant lock-screen notifications the moment big stories break across Australia.
Australian news & events
Politics, sport, weather, local events — all in one swipeable feed, updated around the clock.
Stay ahead of the news cycle
30-second summaries so you're always informed, even on your busiest days.
Loading article…
This publisher's site can't be shown here due to their security settings.
Open full article →No source link available for this article.
✨
Ask AI